When Ginny Mason was diagnosed with inflammatory breast cancer in 1994, she never once heard the word “biomarker.” “Back then, all you got was ER and PR [the estrogen receptor and progesterone ...

Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and ...

Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and ...

C5aR1 expression correlates with increased metastasis risk and poor survival in cSCC patients. The tumor microenvironment, especially fibroblasts, influences C5aR1 expression and cSCC progression.

SKYSCRAPER-01 trial for tiragolumab and atezolizumab in NSCLC showed numerical improvements but failed to meet primary endpoints for survival. Experts argue that TIGIT remains a promising target, with ...

Researchers have identified C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cutaneous squamous cell carcinoma (cSCC), the most common type of metastatic skin cancer.

Advances in genomics and transcriptomics continue to catapult basic and clinical research into a new era. A more comprehensive examination of genomic and transcriptional states allows for ...

Researchers have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings show two distinct patterns of B cell ...

Functional classification of tumor biomarkers by molecular type and clinical applications. Tumor biomarkers are categorized into genetic, protein, epigenetic, and metabolic types, each associated with ...

Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast canc ...